Stephen J.LurieMD, PhD, Senior EditorIndividualAuthorJody W.ZylkeMD, Contributing EditorIndividualAuthor
Copyright 2001 American Medical Association. All Rights Reserved.
Applicable FARS/DFARS Restrictions Apply to Government Use.2001
To the Editor: We would like to comment on
several points raised by Dr Sacks in his Editorial1
accompanying our report of the MIRACL study.2
The findings of the MIRACL study demonstrated that short-term, intensive lipid-lowering
therapy reduces recurrent ischemic cardiovascular events in patients after
ACS. We chose 80 mg/d of atorvastatin, the highest approved dosage with the
greatest lipid-lowering effects, to maximize the likelihood of observing a
benefit of treatment. We agree with Sacks that it remains to be determined
if a lower dose of atorvastatin and/or other statins would have similar effects.
Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters D, Zeiher A, Chaitman BR. Atorvastatin for Acute Coronary Syndromes. JAMA. 2001;286(5):532-535. doi:10.1001/jama.286.5.532